tretinoin and myelin-oligodendrocyte-glycoprotein-(35-55)

Experimental allergic encephalomyelitis (EAE) can be induced in animal models by injecting the MOG35-55 peptide subcutaneously. Dendritic cells (DCs) that are located at the immunization site phagocytose the MOG35-55 peptide. These DCs mature and migrate into the nearest draining lymph nodes (dLNs), then present antigen, resulting in the activation of naive T cells. T helper type 1 (Th1) and Th17 cells are the primary cells involved in EAE progression. All-trans-retinoic acid (AT-RA) has been shown to have beneficial effects on EAE progression; however, whether AT-RA influences DC maturation or mediates other functions is unclear. In the present study, we showed that AT-RA led to the down-regulation of MHC class II, CD80 (B7-1) and CD86 (B7-2) expressed on the surface of DCs that were isolated from dLNs or spleen 3 days post-immunization in an EAE model. Changes to DC function influenced Th1/Th17 subset polarization. Furthermore, the number of CD44(+) monocytes (which might trigger EAE progression) was also significantly decreased in dLNs, spleen, subarachnoid space and the spinal cord parenchyma after AT-RA treatment. These findings are the first to demonstrate that AT-RA impairs the antigen-presenting capacity of DCs, leading to down-regulation of pathogenic Th1 and Th17 inflammatory cell responses and reducing EAE severity.

Topics: Animals; Antigen Presentation; Antigens, CD; Antioxidants; Cell Differentiation; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression Regulation; Histocompatibility Antigens Class II; Immunization; Lymph Nodes; Mice; Mice, Inbred C57BL; Monocytes; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Signal Transduction; Spinal Cord; Spleen; Th1 Cells; Th17 Cells; Tretinoin